Legal & General Group Plc Lowers Stock Position in REGENXBIO Inc. (NASDAQ:RGNX)

Legal & General Group Plc cut its position in REGENXBIO Inc. (NASDAQ:RGNX - Free Report) by 63.1% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 44,823 shares of the biotechnology company's stock after selling 76,793 shares during the quarter. Legal & General Group Plc owned 0.09% of REGENXBIO worth $346,000 as of its most recent SEC filing.

A number of other hedge funds have also recently made changes to their positions in RGNX. JPMorgan Chase & Co. increased its stake in shares of REGENXBIO by 67.0% in the fourth quarter. JPMorgan Chase & Co. now owns 4,136,517 shares of the biotechnology company's stock valued at $31,975,000 after buying an additional 1,659,206 shares during the period. Assenagon Asset Management S.A. increased its position in REGENXBIO by 53.0% in the 4th quarter. Assenagon Asset Management S.A. now owns 856,572 shares of the biotechnology company's stock valued at $6,621,000 after acquiring an additional 296,700 shares during the period. Barclays PLC raised its stake in shares of REGENXBIO by 141.3% during the third quarter. Barclays PLC now owns 116,024 shares of the biotechnology company's stock valued at $1,217,000 after acquiring an additional 67,948 shares during the last quarter. GAMMA Investing LLC lifted its holdings in shares of REGENXBIO by 273.1% during the fourth quarter. GAMMA Investing LLC now owns 3,429 shares of the biotechnology company's stock worth $27,000 after purchasing an additional 2,510 shares during the period. Finally, Geode Capital Management LLC grew its stake in shares of REGENXBIO by 0.5% in the fourth quarter. Geode Capital Management LLC now owns 1,094,225 shares of the biotechnology company's stock worth $8,460,000 after purchasing an additional 5,574 shares during the last quarter. 88.08% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several brokerages have commented on RGNX. Royal Bank of Canada reaffirmed an "outperform" rating and set a $30.00 target price on shares of REGENXBIO in a report on Tuesday, January 21st. Chardan Capital reiterated a "buy" rating and issued a $52.00 target price on shares of REGENXBIO in a report on Thursday, March 20th. The Goldman Sachs Group decreased their target price on shares of REGENXBIO from $14.00 to $12.00 and set a "neutral" rating for the company in a research report on Thursday, April 17th. StockNews.com upgraded shares of REGENXBIO from a "sell" rating to a "hold" rating in a research report on Friday, March 7th. Finally, Leerink Partners set a $24.00 price objective on shares of REGENXBIO in a research report on Tuesday, March 18th. Two investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company's stock. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average price target of $31.63.

REGENXBIO Stock Performance

Shares of REGENXBIO stock traded down $1.84 during trading hours on Tuesday, reaching $7.92. The company's stock had a trading volume of 2,091,941 shares, compared to its average volume of 831,865. The company has a market capitalization of $396.93 million, a P/E ratio of -1.57 and a beta of 1.11. The stock's fifty day simple moving average is $7.25 and its two-hundred day simple moving average is $8.06. REGENXBIO Inc. has a one year low of $5.04 and a one year high of $17.35.

REGENXBIO (NASDAQ:RGNX - Get Free Report) last announced its quarterly earnings results on Thursday, March 13th. The biotechnology company reported ($1.01) earnings per share for the quarter, beating the consensus estimate of ($1.27) by $0.26. The business had revenue of $21.21 million for the quarter, compared to analysts' expectations of $23.70 million. REGENXBIO had a negative net margin of 283.19% and a negative return on equity of 70.65%. As a group, research analysts forecast that REGENXBIO Inc. will post -4.84 earnings per share for the current year.

REGENXBIO Profile

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.